AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24117692 — intervention group
Group type: COMPARATOR
Intervention: 10-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Number of subjects: 360
Study 16373409 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG group (vaginal progesterone after HCG administration)
Number of subjects: 385
Study 16373409 — intervention group
Group type: EXPERIMENTAL
Intervention: OR group (vaginal progesterone at the day of oocyte retrieval)
Number of subjects: 385
Study 16373409 — intervention group
Group type: EXPERIMENTAL
Intervention: ET group (vaginal progesterone at the day of embryo transfer)
Number of subjects: 385
Study 14626871 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 percent mepivacaine hydrochloride with 1:20,000 levonordefrin
Number of subjects: 36
Study 14626871 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent mepivacaine hydrochloride without vasoconstrictor
Number of subjects: 36
Study 14626871 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum recommended dose of mepivacaine
Number of subjects: 36
Study 10797161 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hospital discharge and home-based rehabilitation (median duration, 5 weeks)
Number of subjects: 86
Study 10797161 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient rehabilitation and follow-up care
Number of subjects: 86
Study 10797161 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 86
Study 10797161 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation care
Number of subjects: 86
Study 8618582 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine twice daily
Number of subjects: 285
Study 8618582 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine twice daily
Number of subjects: 285
Study 8618582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 1431190 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal hyperthermia
Number of subjects: 0
Study 1431190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3977557 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 49
Study 3977557 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 49
Study 31779684 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Education Intervention offered every 6 months for 18 months
Number of subjects: 360
Study 31779684 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Education Intervention
Number of subjects: 360
Study 31779684 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-adherence nursing homes)
Number of subjects: 360
Study 28141622 — intervention group
Group type: EXPERIMENTAL
Intervention: Avisetron (8 mg)
Number of subjects: 80
Study 28141622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26556032 — intervention group
Group type: EXPERIMENTAL
Intervention: Online program plus weekly email prompts
Number of subjects: 0
Study 26556032 — intervention group
Group type: COMPARATOR
Intervention: Online program alone
Number of subjects: 0
Study 24180166 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice lozenges (Group A)
Number of subjects: 100
Study 21470071 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen (80 mg t.i.d.)
Number of subjects: 213
Study 21470071 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d.)
Number of subjects: 213
Study 19447425 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg orally daily)
Number of subjects: 212
Study 18042533 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken-based formula
Number of subjects: 38
Study 18042533 — intervention group
Group type: COMPARATOR
Intervention: Soy-based formula
Number of subjects: 38
Study 18042533 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intolerance rates
Number of subjects: 38
Study 14706765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose synthetic conjugated estrogens A (SCE-A), 0.3 mg once daily for 16 weeks
Number of subjects: 71
Study 14706765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 14706765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose synthetic conjugated estrogens A (SCE-A)
Number of subjects: 71
Study 11405527 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Positive Airway Pressure (PPAP)
Number of subjects: 12
Study 11405527 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 12
Study 11405527 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 12
Study 9928648 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl blue tissue adhesive glue
Number of subjects: 163
Study 9928648 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 163
Study 7758607 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin in combination with diuretics
Number of subjects: 0
Study 7758607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of digoxin and diuretics with a blocker of the renin‐angiotensin system (kapothenum)
Number of subjects: 0
Study 3058101 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927 ophthalmic solution
Number of subjects: 12
Study 3058101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 12
Study 30735466 — intervention group
Group type: COMPARATOR
Intervention: Control arm patients from the DEFUSE 3 trial
Number of subjects: 0
Study 30735466 — intervention group
Group type: COMPARATOR
Intervention: Control arm patients with persistent mismatch
Number of subjects: 0
Study 27810987 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥5.7%
Number of subjects: 4095
Study 27810987 — intervention group
Group type: COMPARATOR
Intervention: HbA1c, FPG, and 2hPG
Number of subjects: 4095
Study 25873370 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (PolyE) - 400 mg (‐)‐epigallocatechin‐3‐gallate (EGCG) per day
Number of subjects: 97
Study 25873370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 25873370 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (PolyE)
Number of subjects: 97
Study 23792649 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Tacrolimus QD
Number of subjects: 102
Study 23792649 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus BID
Number of subjects: 102
Study 21296768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block plus i.v. patient-controlled analgesia with morphine
Number of subjects: 92
Study 21296768 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural anaesthesia (EDA)
Number of subjects: 92
Study 21296768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 19795984 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Number of subjects: 134
Study 19795984 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Number of subjects: 134
Study 16492856 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 1.0 mg/kg
Number of subjects: 160
Study 16492856 — intervention group
Group type: COMPARATOR
Intervention: rocuronium 0.6 mg/kg
Number of subjects: 160
Study 15527609 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised patient-specific guidelines following case-finding
Number of subjects: 762
Study 15527609 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 762
Study 12563891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal capsaicin (3 x 10(‐6) mol, dissolved in 70% ethanol)
Number of subjects: 51
Study 12563891 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin vehicle (70% ethanol)
Number of subjects: 51
Study 9308617 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative optimization of hemodynamic parameters (adjusting hemoglobin concentration, oxygen saturation, cardiac output, or afterload until SvO2 was at least 65%)
Number of subjects: 72
Study 9308617 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative optimization of hemodynamic parameters
Number of subjects: 72
Study 9308617 — intervention group
Group type: COMPARATOR
Intervention: Control group (placement of PAC without optimization)
Number of subjects: 72
Study 8154167 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass-surgery
Number of subjects: 0
Study 8154167 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 8154167 — intervention group
Group type: COMPARATOR
Intervention: Palliative PTCA
Number of subjects: 0
Study 3532742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (SK)
Number of subjects: 533
Study 3532742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary SK only
Number of subjects: 533
Study 3532742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plus intracoronary SK
Number of subjects: 533
Study 3532742 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent infarct-related coronary artery
Number of subjects: 533
Study 3532742 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization during intracoronary SK infusion
Number of subjects: 533
Study 3532742 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent coronary occlusion despite thrombolytic therapy
Number of subjects: 533
Study 29633983 — intervention group
Group type: EXPERIMENTAL
Intervention: Water group (substituted water for DBs)
Number of subjects: 71
Study 29633983 — intervention group
Group type: EXPERIMENTAL
Intervention: Water group
Number of subjects: 71
Study 26886719 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate (ThuLEP)
Number of subjects: 127
Study 26886719 — intervention group
Group type: COMPARATOR
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 127
Study 26886719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 127
Study 24797659 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n=10)
Number of subjects: 18
Study 24797659 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (n=8)
Number of subjects: 18
Study 22657939 — intervention group
Group type: EXPERIMENTAL
Intervention: CBL module with case-based scenarios
Number of subjects: 124
Study 22657939 — intervention group
Group type: COMPARATOR
Intervention: CBL module without case-based scenarios
Number of subjects: 124
Study 20157654 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (self-adhesive resin cement)
Number of subjects: 0
Study 20157654 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (resin cement with self-etching primer)
Number of subjects: 0
Study 18414359 — intervention group
Group type: COMPARATOR
Intervention: Desflurane alone (Group A1, n = 27)
Number of subjects: 103
Study 18414359 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with 60% nitrous oxide (Group N1, n = 26)
Number of subjects: 103
Study 18414359 — intervention group
Group type: COMPARATOR
Intervention: Desflurane alone (Group A3, n = 26)
Number of subjects: 103
Study 18414359 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with 60% nitrous oxide (Group N3, n = 24)
Number of subjects: 103
Study 15849974 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatments for acute manic or depressive episodes
Number of subjects: 0
Study 11818112 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 days of 50 microg/day transdermal 17beta‐estradiol (TE) administration
Number of subjects: 30
Study 11818112 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 days of 100 microg/day transdermal 17beta‐estradiol (Estraderm‐Ciba) administration
Number of subjects: 30
Study 11818112 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous total hysterectomy with intact ovaries)
Number of subjects: 30
Study 10385059 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (colloidal bismuth subcitrate, tetracycline, metronidazole) for 2 weeks
Number of subjects: 112
Study 10385059 — intervention group
Group type: COMPARATOR
Intervention: Sucralphate (1 g, q.i.d.) for 4 weeks
Number of subjects: 112
Study 10385059 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg, b.d.) for 4 weeks
Number of subjects: 112
Study 8678767 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 34
Study 8678767 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiological imaging
Number of subjects: 34
Study 1875423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundal Height (FH) method
Number of subjects: 100
Study 1875423 — intervention group
Group type: COMPARATOR
Intervention: Percentage of Maternal Abdominal Length (PMAL) method
Number of subjects: 100
Study 6123330 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bunitrolol (BU)
Number of subjects: 9
Study 6123330 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methypranol (ME)
Number of subjects: 9
Study 6123330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31308556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Intense Pulse Light and topical eflornithine therapy (topical eflornithine applied twice a day and IPL session once a month for 6 months)
Number of subjects: 78
Study 31308556 — intervention group
Group type: COMPARATOR
Intervention: Intense Pulse Light therapy alone (IPL monthly sessions for 6 months)
Number of subjects: 78
Study 28372653 — intervention group
Group type: EXPERIMENTAL
Intervention: 20ml of 0.75% ropivacaine with 1ml (4mg) of perineural dexamethasone (Dpn group, n=20)
Number of subjects: 60
Study 28372653 — intervention group
Group type: EXPERIMENTAL
Intervention: 20ml of 0.75% ropivacaine with 1ml of isotonic saline and intravenous 4mg dexamethasone (Div group, n=20)
Number of subjects: 60
Study 28372653 — intervention group
Group type: COMPARATOR
Intervention: 20ml of 0.75% ropivacaine with 1ml of isotonic saline (C group, n=20)
Number of subjects: 60
Study 25312782 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous continuous carbon dioxide tension (PtcCO2) monitoring
Number of subjects: 50
Study 25312782 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded to PtcCO2 values)
Number of subjects: 50
Study 25312782 — intervention group
Group type: EXPERIMENTAL
Intervention: PtcCO2 and PaCO2 measurements
Number of subjects: 50
Study 23525419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day IPC (3 cycles of 5' upper-arm ischemia and 5' reperfusion)
Number of subjects: 30
Study 23525419 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day IPC (single daily episodes of IPC for 6 days prior to IR)
Number of subjects: 30
Study 23525419 — intervention group
Group type: COMPARATOR
Intervention: IR alone
Number of subjects: 30
Study 23525419 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (cyclooxygenase‐2 inhibitor)
Number of subjects: 30
Study 23525419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21489168 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard concentration intranasal fentanyl (SINF)
Number of subjects: 189
Study 21489168 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly concentrated intranasal fentanyl (HINF)
Number of subjects: 189
Study 18024250 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 16
Study 18024250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1%
Number of subjects: 16
Study 18024250 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 17230032 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 or 20 mg/day
Number of subjects: 225
Study 11869725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fodor's variant of the Wason selection task
Number of subjects: 0
Study 11869725 — intervention group
Group type: COMPARATOR
Intervention: Original Wason selection task
Number of subjects: 0
Study 10659374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone use (Motorola GSM 8700) during a 5-minute reading task
Number of subjects: 20
Study 10659374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone use (Motorola GSM 8700) during a 6-minute exposure while speaking
Number of subjects: 20
Study 10659374 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call while performing a secondary task (switching attention test)
Number of subjects: 20
Study 7606728 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxyspergualin (DSG) at doses of 50 mg/m2 (dl I) or 150 mg/m2 (dl II and III) administered on days 1-7.
Number of subjects: 24
Study 7606728 — intervention group
Group type: EXPERIMENTAL
Intervention: L6 mAb administered at a fixed dose of 200 mg/m2 on days 1-5.
Number of subjects: 24
Study 7606728 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxyspergualin (DSG) at a starting dose of 150 mg/m2/day recommended for Phase II trials.
Number of subjects: 24
Study 2360750 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed intervention for smoking cessation, initiated in the hospital and maintained through telephone contact, including an 18-page manual for relapse prevention.
Number of subjects: 173
Study 2360750 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 173
Study 2360750 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed intervention for smoking cessation, assuming all surviving patients lost to follow-up were smoking.
Number of subjects: 173
Study 341955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta-carotene
Number of subjects: 0
Study 341955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6758746 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 5 mg
Number of subjects: 10
Study 6758746 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 10
Study 30485123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment protocol
Number of subjects: 70
Study 30485123 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises focusing on scheduled sex and motivations for sex
Number of subjects: 70
Study 30485123 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 70
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital EPR (n=14)
Number of subjects: 58
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Home EPR (n=15)
Number of subjects: 58
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital EPR and Home EPR (n=14)
Number of subjects: 58
Study 29516853 — intervention group
Group type: COMPARATOR
Intervention: Control (n=15)
Number of subjects: 58
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital EPR
Number of subjects: 58
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Home EPR
Number of subjects: 58
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 58
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapists' views
Number of subjects: 58
Study 29516853 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic analysis
Number of subjects: 58
Study 28027630 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNSs (20 g daily)
Number of subjects: 168
Study 28027630 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit (3 pieces daily)
Number of subjects: 168
Study 28027630 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 168
Study 28027630 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNSs
Number of subjects: 168
Study 28027630 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit
Number of subjects: 168
Study 28027630 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 168
Study 24271567 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-guided lesson of TEE psychomotor skills with the simulator
Number of subjects: 0
Study 24271567 — intervention group
Group type: COMPARATOR
Intervention: Self-directed slide presentation of TEE psychomotor skills with the simulator
Number of subjects: 0
Study 24654201 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial hydration (AH)
Number of subjects: 122
Study 21063144 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning during a 2-ball quick rotation task
Number of subjects: 18
Study 21063144 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning
Number of subjects: 18
Study 17690809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol (Experiment 1)
Number of subjects: 0
Study 17690809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g/kg alcohol (Experiment 2)
Number of subjects: 0
Study 17690809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17690809 — intervention group
Group type: COMPARATOR
Intervention: No-beverage control group
Number of subjects: 0
Study 15637138 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug induction treatment with intermediate-dose cytarabine and mitoxantrone salvage treatment
Number of subjects: 91
Study 15637138 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial induction treatment
Number of subjects: 91
Study 15637138 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 91
Study 15637138 — intervention group
Group type: EXPERIMENTAL
Intervention: HOX11L2 and SIL-TAL1 T-ALL
Number of subjects: 91
Study 15637138 — intervention group
Group type: EXPERIMENTAL
Intervention: HOX11L2 T-ALL
Number of subjects: 91
Study 15637138 — intervention group
Group type: EXPERIMENTAL
Intervention: Allografting in HOX11 T-ALL patients
Number of subjects: 91
Study 12236426 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV+3TC
Number of subjects: 25
Study 12236426 — intervention group
Group type: COMPARATOR
Intervention: ZDV+3TC+NFV
Number of subjects: 25
Study 10431340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing amyloglucosidase and glucose oxidase (enzyme solution)
Number of subjects: 33
Study 10431340 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 33
Study 7648979 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct contact dissolution with methyl tert‐butyl ether
Number of subjects: 60